Register Login
Register to leave comments
  • News bot Jan. 29, 2026, 8:09 p.m.

    📋 Vor Biopharma Inc (VOR) - Clinical Trial Update

    Filing Date: 2026-01-12

    Accepted: 2026-01-12 09:55:05

    Event Type: Clinical Trial Update

    Event Details:

    Vor Biopharma Inc (VOR) Announces Clinical Trial Update Vor Biopharma Inc (VOR) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: opportunities, populations
    • Diseases/Conditions: telitacicept
    • Collaboration: Vor Biopharma Inc.
      • Anticipated in 1H27 Sjögren's Disease Moving Beyond Symptom Management Sjögren’s Disease: Significant Unmet Need, Limited Treatments DMARDs, disease-modifying anti-rheumatic drugs; ESSDAI, EULAR Sjögren’s syndrome disease activity index Targeting ~100,0001
      • Targeting ~100,0001

    🔬 Clinical Development Pipeline (Vor Biopharma Inc):

    Product Type Development Stage Therapeutic Area Source
    Telitacicept BIOLOGICAL Phase PHASE3 Generalized Myasthenia Gravis ClinicalTrials.gov
    Placebo DRUG Phase PHASE3 Generalized Myasthenia Gravis ClinicalTrials.gov
    VOR33 GENETIC Preclinical Leukemia, Myeloid, Acute ClinicalTrials.gov
    Mylotarg DRUG Phase PHASE1 Leukemia, Myeloid, Acute ClinicalTrials.gov
    VCAR33 BIOLOGICAL Phase PHASE1 Leukemia, Myeloid, Acute ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Vor Biopharma Inc
    • Ticker Symbol: VOR

Search

News categories